Skip to main content

Molecular understanding and clinical aspects of immunotherapy in the treatment of cancer

Molecular Cancer invites submissions to this article collection. Topics of interest include, but are not limited to, adoptive cellular immunotherapy, chimeric antigen receptor T-cell (CAR-T) immunotherapy, immune checkpoint inhibitors, modulators of tumor microenvironment, and drug resistance mechanisms in immunotherapy.

The collection is open to submissions from August 15th to September 15th 2023.


  1. CAR T cell-based therapies have revolutionized the treatment of hematological malignancies such as leukemia and lymphoma within the last years. In contrast to the success in hematological cancers, the treatmen...

    Authors: Lusine Hovhannisyan, Carsten Riether, Daniel M. Aebersold, Michaela Medová and Yitzhak Zimmer
    Citation: Molecular Cancer 2023 22:82
  2. Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical application. Single-cell sequencing ...

    Authors: Shengkang Huang, Xinyu Wang, Yu Wang, Yajing Wang, Chenglong Fang, Yazhuo Wang, Sifei Chen, Runkai Chen, Tao Lei, Yuchen Zhang, Xinjie Xu and Yuhua Li
    Citation: Molecular Cancer 2023 22:80
  3. The development of cancer immunotherapeutic strategies relies on the identification and validation of optimal target tumor antigens, which should be tumor-specific as well as able to elicit a swift and potent ...

    Authors: Maria Tagliamonte, Beatrice Cavalluzzo, Angela Mauriello, Concetta Ragone, Franco M. Buonaguro, Maria Lina Tornesello and Luigi Buonaguro
    Citation: Molecular Cancer 2023 22:75
  4. Mesenchymal gastrointestinal cancers are represented by the gastrointestinal stromal tumors (GISTs) which occur throughout the whole gastrointestinal tract, and affect human health and economy globally. Curati...

    Authors: Bo Li, Hui Chen, Shaohua Yang, Feng Chen, Liangliang Xu, Yan Li, Mingzhe Li, Chengming Zhu, Fangyuan Shao, Xinhua Zhang, Chuxia Deng, Leli Zeng, Yulong He and Changhua Zhang
    Citation: Molecular Cancer 2023 22:71
  5. The development of head and neck squamous cell carcinoma (HNSCC) is a multi-step process, and its survival depends on a complex tumor ecosystem, which not only promotes tumor growth but also helps to protect t...

    Authors: Yingying Gong, Lisha Bao, Tong Xu, Xiaofen Yi, Jinming Chen, Shanshan Wang, Zongfu Pan, Ping Huang and Minghua Ge
    Citation: Molecular Cancer 2023 22:68
  6. N6-methyladenosine (m6A) methylation is the most universal internal modification in eukaryotic mRNA. With elaborate functions executed by m6A writers, erasers, and readers, m6A modulation is involved in myriad ph...

    Authors: Xiaoxue Cao, Qishun Geng, Danping Fan, Qiong Wang, Xing Wang, Mengxiao Zhang, Lu Zhao, Yi Jiao, Tingting Deng, Honglin Liu, Jing Zhou, Liqun Jia and Cheng Xiao
    Citation: Molecular Cancer 2023 22:42
  7. Ongoing research has revealed that the existence of cancer stem cells (CSCs) is one of the biggest obstacles in the current cancer therapy. CSCs make an influential function in tumor progression, recurrence an...

    Authors: Bo Wu, Xiang Shi, Meixi Jiang and Hongxu Liu
    Citation: Molecular Cancer 2023 22:38
  8. Several mechanisms and cell types are involved in the regulation of the immune response. These include mostly regulatory T cells (Tregs), regulatory macrophages (Mregs), myeloid suppressor cells (MDSCs) and ot...

    Authors: María Iglesias-Escudero, Noelia Arias-González and Eva Martínez-Cáceres
    Citation: Molecular Cancer 2023 22:26
  9. Cancer remains a leading cause of death worldwide, placing a significant burden on healthcare systems as well as the global economy. Rare cancers comprise a group of about 200 cancers that individually occur a...

    Authors: Sneha Vivekanandhan, Deborah Bahr, Ashish Kothari, Mohammed Ali Ashary, Mizba Baksh and Emmanuel Gabriel
    Citation: Molecular Cancer 2023 22:23
  10. The quality and quantity of tumor neoantigens derived from tumor mutations determines the fate of the immune response in cancer. Frameshift mutations elicit better tumor neoantigens, especially when they are n...

    Authors: Daniel Meraviglia-Crivelli, Helena Villanueva, Angelina Zheleva, María Villalba-Esparza, Beatriz Moreno, Ashwathi Puravankara Menon, Alfonso Calvo, Javier Cebollero, Martin Barainka, Igor Ruiz de los Mozos, Carlos Huesa-Berral and Fernando Pastor
    Citation: Molecular Cancer 2022 21:211
  11. Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing technology represents a significant breakthrough in personalized immunotherapy for human cancer. This strategy uses genetic mod...

    Authors: Chunrun Qu, Hao Zhang, Hui Cao, Lanhua Tang, Haoyang Mo, Fangkun Liu, Liyang Zhang, Zhenjie Yi, Lifu Long, Luzhe Yan, Zeyu Wang, Nan Zhang, Peng Luo, Jian Zhang, Zaoqu Liu, Weijie Ye…
    Citation: Molecular Cancer 2022 21:201